Rituximab is more effective to treat rheumatoid arthritis compared to a second anti-TNFalpha blockers.
Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study / Axel, Finckh; Jacques Eric, Gottenberg; Chiedzo, Mpofu; William, G. Bensen; Andrea, Rubbert Roth; Fedra, Irazoque; Victor, Martı’nez Taboada; Carol, Chung; Lykke, Hinsch Gylvin; Ferri, Clodoveo; Paul, Emery. - In: ARTHRITIS AND RHEUMATISM. - ISSN 1529-0131. - STAMPA. - 64:10(2012), pp. S198-S198. (Intervento presentato al convegno ACR tenutosi a Washington nel 9-14 November 2012).
Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study
FERRI, Clodoveo;
2012
Abstract
Rituximab is more effective to treat rheumatoid arthritis compared to a second anti-TNFalpha blockers.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
